Annovis Bio, Inc.
ANVS•NYSE•Healthcare•Biotechnology

About Annovis Bio

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer’s disease, as well as in phase 3 to treat parkinson’s disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer’s disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOMaria Maccecchini
Founded2008
IPO DateJanuary 29, 2020
Employees15
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNYSE (NYSE)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.annovisbio.com
Phone484 875 3192
Address
101 Lindenwood Drive, Suite 225 Malvern, Pennsylvania 19355 United States

Corporate Identifiers

CIK0001477845
CUSIP03615A108
ISINUS03615A1088
EIN26-2540421
SIC2834

Leadership Team & Key Executives

Dr. Maria L. Maccecchini Ph.D.
Founder, Chief Executive Officer, President and Executive Director
Mark Patrick Guerin C.M.A., CPA, CFM
Chief Financial Officer
Dr. Cheng Fang Ph.D.
Senior Vice President of Research and Development
Eve M. Damiano M.S., RAC
Senior Vice President of Regulatory Operations
Melissa Gaines
Senior Vice President of Clinical Operations
Blake Jensen M.B.A.
Head of Quality
Hilda Maibach
Senior Vice President of Statistics